KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) Operating Expenses (2016 - 2025)

TherapeuticsMD (TXMD) has disclosed Operating Expenses for 16 consecutive years, with $1.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Operating Expenses fell 2.08% year-over-year to $1.6 million, compared with a TTM value of $5.3 million through Sep 2025, down 35.58%, and an annual FY2024 reading of $6.5 million, down 33.63% over the prior year.
  • Operating Expenses was $1.6 million for Q3 2025 at TherapeuticsMD, down from $2.1 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $60.0 million in Q3 2021 and bottomed at -$77.8 million in Q4 2021.
  • Average Operating Expenses over 5 years is $6.3 million, with a median of $2.1 million recorded in 2023.
  • The sharpest move saw Operating Expenses tumbled 250.77% in 2021, then soared 125.87% in 2022.
  • Year by year, Operating Expenses stood at -$77.8 million in 2021, then skyrocketed by 125.87% to $20.1 million in 2022, then tumbled by 89.5% to $2.1 million in 2023, then crashed by 82.87% to $362000.0 in 2024, then skyrocketed by 354.7% to $1.6 million in 2025.
  • Business Quant data shows Operating Expenses for TXMD at $1.6 million in Q3 2025, $2.1 million in Q2 2025, and $1.3 million in Q1 2025.